Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours

NCT04839991 is registered in ClinicalTrials.gov with Crescendo Biologics Ltd. as lead sponsor.

NCT NCT04839991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04839991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients With PSMA+ Advanced and/or Metastatic Solid Tumours
Lead sponsor
Crescendo Biologics Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
June 8, 2021
Completion date
September 25, 2024
Enrollment
70 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced and/or metastatic solid tumours